Share on StockTwits

Shares of Insulet (NASDAQ:PODD) have received an average recommendation of “Buy” from the eleven ratings firms that are currently covering the company, Stock Ratings Network reports. Three investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $45.33.

In other Insulet news, CEO Duane Desisto unloaded 20,000 shares of the company’s stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $34.23, for a total value of $684,600.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Insulet (NASDAQ:PODD) opened at 34.66 on Monday. Insulet has a 1-year low of $30.04 and a 1-year high of $51.31. The stock has a 50-day moving average of $37.21 and a 200-day moving average of $40.63. The company’s market cap is $1.937 billion.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. The company had revenue of $72.00 million for the quarter, compared to the consensus estimate of $72.94 million. During the same quarter in the previous year, the company posted ($0.20) earnings per share. The company’s revenue for the quarter was up 19.8% on a year-over-year basis. On average, analysts predict that Insulet will post $-0.12 earnings per share for the current fiscal year.

Separately, analysts at Canaccord Genuity cut their price target on shares of Insulet from $40.00 to $39.00 in a research note on Friday, August 8th.

Insulet Corporation is primarily engaged in the development, manufacturing and sale of its OmniPod Insulin Management System (NASDAQ:PODD).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.